This is consistent with evidence that in blast crisis CML patients, PP2A activity was shown to be impaired due to the overexpression of the PP2A cellular antagonist, SET [57, 58]. This evidence concerns the gene SET and chronic myelogenous leukemia, BCR-ABL1 positive.